Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
1.408
+0.058 (4.27%)
Nov 5, 2024, 10:22 AM EST - Market open
Kairos Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 1.62 | 1.63 | 0.48 | 1.76 |
| Research & Development | 0.27 | 0.08 | 0.09 | 0.18 |
| Operating Expenses | 1.89 | 1.71 | 0.57 | 1.94 |
| Operating Income | -1.89 | -1.71 | -0.57 | -1.94 |
| Interest Expense | -0.12 | -0.1 | -0.46 | -0.16 |
| Other Non Operating Income (Expenses) | - | - | -0.02 | -0.04 |
| Pretax Income | -2.01 | -1.81 | -1.05 | -2.15 |
| Net Income | -2.01 | -1.81 | -1.05 | -2.15 |
| Net Income to Common | -2.01 | -1.81 | -1.05 | -2.15 |
| Shares Outstanding (Basic) | 10 | 10 | 10 | 9 |
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 9 |
| Shares Change (YoY) | 1.77% | 1.42% | 11.86% | - |
| EPS (Basic) | -0.19 | -0.17 | -0.10 | -0.23 |
| EPS (Diluted) | -0.19 | -0.17 | -0.10 | -0.23 |
| Free Cash Flow | 0.03 | 0.08 | -0.35 | -0.41 |
| Free Cash Flow Per Share | 0.00 | 0.01 | -0.03 | -0.05 |
| EBITDA | -1.73 | -1.55 | -0.41 | -1.85 |
| D&A For EBITDA | 0.16 | 0.16 | 0.16 | 0.1 |
| EBIT | -1.89 | -1.71 | -0.57 | -1.94 |
Source: S&P Capital IQ. Standard template.
Financial Sources.